Viking Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Viking Therapeutics reports significant clinical progress for its metabolic and endocrine disorder pipeline, including positive Phase 2 results for oral and subcutaneous VK2735 in obesity and VK2809 in NASH/MASH, alongside Phase 3 initiations.
NASDAQ
Viking Therapeutics' 2024 10-K filing highlights clinical advancements in VK2735 and VK2809, alongside financial stability for continued development.
NASDAQ
Viking Therapeutics' 10-K filing details the company's clinical advancements, financial standing, and future strategies in developing therapies for metabolic and endocrine disorders.